Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 5

WCLC Updates in Locally Advanced NSCLC

March 5, 2021
Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center

Sarah Goldberg, MD, MPH, Yale School of Medicine

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

Heather A. Wakelee, MD, Stanford University Medical Center

Key opinion leaders provide insights on chemotherapy and radiotherapy in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC).

Data from the following clinical trial are discussed: 

  •  OA02.03 - Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced Stage III NSCLC: KEYNOTE-799